Literature DB >> 21706236

Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma.

Yingqi Hua1, Xiaofang Jia, Mengxiong Sun, Longpo Zheng, Lin Yin, Lijun Zhang, Zhengdong Cai.   

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. To identify new biomarkers for early diagnosis of OS and novel therapeutic candidates, we carried out a plasma membrane proteomic study based on two-dimensional electrophoresis (2DE). The OS cell line MG-63 and the human osteoblastic cell line hFOB1.19 were adopted as the comparison model. We extracted plasma membrane by aqueous two-phase partition extraction. The proteins were separated through 2DE. We analyzed the differentially expressed proteins by Imagemaster software and then identified them by liquid chromatography-tandem mass spectrometry, and the location and function of differential proteins were searched through the Gene Ontology database. In total, 220 protein spots were separated by 2DE. Seven proteins with more than 2.0-folds of difference were successfully identified from 13 gel spots, with 6 up-regulated and 1 down-regulated. Gene Ontology analysis of the differentially expressed proteins indicated that these proteins were involved in seven kinds of functions including binding, structural, cell motility, receptor activity, electron carrier activity, NADH dehydrogenase (ubiquinone) activity, and transcription repressor activity. The up-regulation of NDRG1 was verified in osteosarcoma through Western blotting and by immunohistochemistry in paraffin-embedded tissues. The plasma membrane proteins identified in this study may provide new insights into osteosarcoma cancer biology and potential diagnostic and therapeutic biomarkers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706236     DOI: 10.1007/s13277-011-0203-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

Review 1.  Proteomics and the dynamic plasma membrane: Quo Vadis?

Authors:  Richard R Sprenger; Ole N Jensen
Journal:  Proteomics       Date:  2010-11-02       Impact factor: 3.984

2.  Identification of alternatively spliced GRIM-19 mRNA in kidney cancer tissues.

Authors:  Xuelian He; Xinmin Cao
Journal:  J Hum Genet       Date:  2010-05-27       Impact factor: 3.172

3.  Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.

Authors:  Eiko Hayashi; Yasuhiro Kuramitsu; Futoshi Okada; Masanori Fujimoto; Xiulian Zhang; Masanobu Kobayashi; Norio Iizuka; Yoshiya Ueyama; Kazuyuki Nakamura
Journal:  Proteomics       Date:  2005-03       Impact factor: 3.984

Review 4.  Plasma membrane proteomics and its application in clinical cancer biomarker discovery.

Authors:  Rikke Leth-Larsen; Rikke R Lund; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2010-04-08       Impact factor: 5.911

5.  Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.

Authors:  Y Li; Q Liang; Y-q Wen; L-l Chen; L-t Wang; Y-l Liu; C-q Luo; H-z Liang; M-t Li; Z Li
Journal:  Cancer Genet Cytogenet       Date:  2010-04-15

Review 6.  Molecular pathology in sarcomas.

Authors:  E de Alava
Journal:  Clin Transl Oncol       Date:  2007-03       Impact factor: 3.405

7.  Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis.

Authors:  Lijun Zhang; Xia Peng; Zhanqin Zhang; Yanling Feng; Xiaofang Jia; Yuxin Shi; Hua Yang; Zhiyong Zhang; Xiaonan Zhang; Liwen Liu; Lin Yin; Zhenghong Yuan
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

8.  N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cells.

Authors:  Toru Matsugaki; Michihisa Zenmyo; Koji Hiraoka; Nobuhiro Fukushima; Takanori Shoda; Setsuro Komiya; Mayumi Ono; Michihiko Kuwano; Kensei Nagata
Journal:  Oncol Rep       Date:  2010-09       Impact factor: 3.906

9.  HLA phenotypes in patients who have osteosarcoma.

Authors:  T Shimizu; M Chigira; M Nagase; H Watanabe; E Udagawa
Journal:  J Bone Joint Surg Am       Date:  1990-01       Impact factor: 5.284

10.  Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets.

Authors:  Cecilia Folio; María I Mora; Marta Zalacain; Fernando J Corrales; Victor Segura; Luis Sierrasesúmaga; Gemma Toledo; Mikel San-Julián; Ana Patiño-García
Journal:  J Proteome Res       Date:  2009-08       Impact factor: 4.466

View more
  15 in total

1.  CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.

Authors:  Mo Zhai; Lin Cong; Yaxin Han; Guanjun Tu
Journal:  Tumour Biol       Date:  2013-09-08

2.  SPAG9 is overexpressed in osteosarcoma, and regulates cell proliferation and invasion through regulation of JunD.

Authors:  Chi Xiao; Lin Fu; Chongnan Yan; Fenyong Shou; Qi Liu; Lei Li; Shaoqian Cui; Jingzhu Duan; Guoxin Jin; Jianhua Chen; Yuanming Bian; Xu Wang; Huan Wang
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

3.  Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.

Authors:  Wan I Wan-Ibrahim; Vivek A Singh; Onn H Hashim; Puteri S Abdul-Rahman
Journal:  Mol Med       Date:  2015-11-13       Impact factor: 6.354

4.  Proteomic technologies for the study of osteosarcoma.

Authors:  Stephanie D Byrum; Charity L Washam; Corey O Montgomery; Alan J Tackett; Larry J Suva
Journal:  Sarcoma       Date:  2012-03-06

5.  Cancer cell-specific oligopeptides selected by an integrated microfluidic system from a phage display library for ovarian cancer diagnosis.

Authors:  Chih-Hung Wang; Chen-Hsun Weng; Yu-Jui Che; Kuan Wang; Gwo-Bin Lee
Journal:  Theranostics       Date:  2015-02-05       Impact factor: 11.556

6.  Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin.

Authors:  Jahnabi Roy; Kathryn L Wycislo; Holly Pondenis; Timothy M Fan; Aditi Das
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

7.  Serum tumor markers in pediatric osteosarcoma: a summary review.

Authors:  Yulia A Savitskaya; Genaro Rico-Martínez; Luis Miguel Linares-González; Ernesto Andrés Delgado-Cedillo; René Téllez-Gastelum; Alfonso Benito Alfaro-Rodríguez; Antonio Redón-Tavera; José Clemente Ibarra-Ponce de León
Journal:  Clin Sarcoma Res       Date:  2012-03-23

8.  Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts.

Authors:  Milan Milovancev; Ian Hilgart-Martiszus; Michael J McNamara; Cheri P Goodall; Bernard Seguin; Shay Bracha; Samanthi I Wickramasekara
Journal:  BMC Vet Res       Date:  2013-06-13       Impact factor: 2.741

9.  Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.

Authors:  J Posthumadeboer; S R Piersma; T V Pham; P W van Egmond; J C Knol; A M Cleton-Jansen; M A van Geer; V W van Beusechem; G J L Kaspers; B J van Royen; C R Jiménez; M N Helder
Journal:  Br J Cancer       Date:  2013-09-24       Impact factor: 7.640

10.  NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.

Authors:  Hongsheng Wang; Wen Li; Jing Xu; Tao Zhang; Dongqing Zuo; Zifei Zhou; Binhui Lin; Gangyang Wang; Zhuoying Wang; Wei Sun; Mengxiong Sun; Shimin Chang; Zhengdong Cai; Yingqi Hua
Journal:  Cell Death Dis       Date:  2017-09-14       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.